Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Clovis Oncology Inc (CLVSQ)

Clovis Oncology Inc (CLVSQ)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 2,182
  • Shares Outstanding, K 145,487
  • Annual Sales, $ 148,760 K
  • Annual Income, $ -264,520 K
  • 60-Month Beta 0.67
  • Price/Sales 0.02
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade CLVSQ with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -1.75
  • Most Recent Earnings $-0.39 on 11/09/22
  • Latest Earnings Date 01/03/24
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.0102 +47.06%
on 07/06/23
0.0360 -58.33%
on 06/12/23
-0.0120 (-44.44%)
since 06/09/23
3-Month
0.0102 +47.06%
on 07/06/23
0.0753 -80.08%
on 05/01/23
-0.0195 (-56.52%)
since 04/10/23
52-Week
0.0102 +47.06%
on 07/06/23
2.8700 -99.48%
on 07/13/22
-2.7550 (-99.46%)
since 07/08/22

Most Recent Stories

More News
Coherus BioSciences (CHRS) Reports Q4 Loss, Misses Revenue Estimates

Coherus BioSciences (CHRS) delivered earnings and revenue surprises of 6.25% and 0.81%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

CHRS : 2.04 (+5.70%)
CLVSQ : 0.0150 (+45.63%)
Seer, Inc. (SEER) Reports Q4 Loss, Misses Revenue Estimates

Seer, Inc. (SEER) delivered earnings and revenue surprises of 14.29% and 0.69%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

SEER : 1.9100 (+9.14%)
CLVSQ : 0.0150 (+45.63%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

Clovis Oncology, Inc. is a biopharmaceutical companyfocused on acquiring, developing and commercializing innovative anti-cancer agents.'Clovis has only one marketed drug in its portfolio a poly ADP-ribose polymerase inhibitor, namely Rubraca that is approved for the treatment of certain patients with...

See More

Key Turning Points

3rd Resistance Point 0.0244
2nd Resistance Point 0.0207
1st Resistance Point 0.0178
Last Price 0.0150
1st Support Level 0.0112
2nd Support Level 0.0075
3rd Support Level 0.0046

See More

52-Week High 2.8700
Fibonacci 61.8% 1.7776
Fibonacci 50% 1.4401
Fibonacci 38.2% 1.1026
Last Price 0.0150
52-Week Low 0.0102

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar